Simpler, Less Expensive Test for Ulcer Bug

Publication
Article
OncologyONCOLOGY Vol 12 No 1
Volume 12
Issue 1

Researchers from the University of Wurzburg in Germany have determined that a simple antibody test may be as effective in detecting Helicobacter pylori infection as the more invasive procedures that are currently used. They reported their findings

Researchers from the University of Wurzburg in Germany have determined that a simple antibody test may be as effective in detecting Helicobacter pylori infection as the more invasive procedures that are currently used. They reported their findings in the December 1997 issue of the Journal of Clinical Microbiology.

In the study, the researchers compared the sensitivity of a test for Hpylori-specific immunoglobulin G (IgG) antibodies with the standard tests in clinical practice. The antibody test had a 98% sensitivity, correctly diagnosing 58 of the 59 patients diagnosed by standard methods.

“The current gold standard tests in clinical practice, endoscopy for histology and the rapid urease test, are limited by their relatively high costs and the need for invasive procedures,” say the researchers. “Determination of antibodies against H pylori presents a relatively simple diagnostic method, with kits that can be used to perform this method now...readily available from commercial sources.”

Helicobacter pylori is a bacterium that lives in the harsh acidic environment of the stomach. The cause of most duodenal ulcers and an estimated 70% to 80% of gastric ulcers, H pylori is considered to be a risk factor for stomach cancer. 

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.